pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Prescription patterns according to medication category in COPD patients
| 2015 | 2016 | 2017 | 2018 | CAGR of the no. Of patients (%) | CAGR of the no. of prescriptions (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients, (%) | No. of Prescriptions, (%) | No. of Patients, (%) | No. of Prescriptions, (%) | No. of Patients, (%) | No. of Prescriptions, (%) | No. of Patients, (%) | No. of Prescriptions, (%) | |||
| Inhaled Medication |
9,227(47.1) | 32,212(42.3) | 9,713(49.1) | 33,485(44.6) | 9,500(50.9) | 32,782(46.6) | 9,285(51.5) | 32,386(47.2) | 0.2 | 0.2 |
| ICS | 820(4.2) | 2,546(3.3) | 886(4.5) | 3,069(4.1) | 818(4.4) | 2,728(3.9) | 809(4.5) | 2,829(4.1) | -0.4 | 3.6 |
| ICS/LABA | 2,357(12.0) | 8,134(10.7) | 2,417(12.2) | 8,002(10.7) | 2,346(12.6) | 7,929(11.3) | 2,253(12.5) | 7,655(11.1) | -1.5 | -2.0 |
| LABA | 536(2.7) | 1,655(2.2) | 367(1.9) | 1,130(1.5) | 206(1.1) | 619(0.9) | 126(0.7) | 385(0.6) | -38.3 | -38.5 |
| LAMA | 2,466(12.6) | 9,547(12.5) | 2,438(12.3) | 8,905(11.9) | 2,138(11.4) | 7,567(10.8) | 1,835(10.2) | 6,509(9.5) | -9.4 | -12.0 |
| LAMA/LABA | 197(1.0) | 384(0.5) | 755(3.8) | 2,253(3.0) | 1212(6.5) | 3,724(5.3) | 1,590(8.8) | 4,857(7.1) | 100.6 | 133.0 |
| SABA | 858(4.4) | 2,854(3.7) | 2,005(10.1) | 7,098(9.5) | 1,949(10.4) | 7,084(10.1) | 812(4.5) | 3,227(4.7) | -1.8 | 4.2 |
| SAMA | 1,993(10.2) | 7,092(9.3) | 845(4.3) | 3,028(4.0) | 831(4.4) | 3,131(4.5) | 1,860(10.3) | 6,924(10.1) | -2.3 | -0.8 |
| Oral Medication |
10,364(52.9) | 44,015(57.7) | 10,062(50.9) | 41,623(55.4) | 9,181(49.1) | 37,556(53.4) | 8,736(48.5) | 36,283(52.8) | -5.5 | -6.2 |
| LTRA | 2,130(10.9) | 8,781(11.5) | 2,233(11.3) | 9087(12.1) | 2,084(11.2) | 8,531(12.1) | 2,114(11.7) | 8139(11.9) | -0.3 | -2.5 |
| OCS | 1,948(9.9) | 6,042(7.9) | 1878(9.5) | 5839(7.8) | 1,742(9.3) | 5,229(7.4) | 1,636(9.1) | 5,407(7.) | -5.7 | -3.6 |
| PDE-4 inhibitor | 127(0.6) | 572(0.8) | 153(0.8) | 662(0.9) | 134(0.7) | 584(0.8) | 168(0.9) | 672(1.0) | 9.8 | 5.5 |
| Systemic beta agonist | 1,559(7.5) | 6,642(7.9) | 1,373(6.5) | 5,372(6.4) | 1,101(5.4) | 4,293(5.4) | 969(4.9) | 3,841(5.0) | -14.7 | -16.7 |
| Xanthines | 4,600(23.5) | 21,978(28.8) | 4,421(22.4) | 20,639(27.5) | 4,120(22.1) | 18,919(26.9) | 3,849(21.4) | 18,224(26.5) | -5.8% | -6.1% |
| Total (Sum) | 19,591 | 76,227 | 19,775 | 75,108 | 18,681 | 70,338 | 18,021 | 68,669 | -2.7 | -3.4 |
The sum of patients exceeds the total number of patients in Table 1 because it includes prescription of concomitant medication.
*The sum of Inhaled medication or oral medication categories. ICS: inhaled corticosteroid LAMA: long-acting muscarinic antagonist, LABA: long acting β2 agonist, SABA: short acting β2 agonist, SAMA: short-acting muscarinic antagonist, LTRA: leukotriene receptor antagonist, OCS: oral corticosteroids, PDE-4 inhibitor: phosphodiesterase-4 inhibitor, CAGR: compound annual growth rate by 4 years. When two or more types of drugs were prescribed in one prescription, they were duplicated in each drug prescription classification and were calculated by removing duplicates when calculating the number of patients.